1 results match your criteria: "and Lilly Laboratory for Clinical Research[Affiliation]"
Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Pharmacotherapy
February 1999
Eli Lilly and Company, Lilly Research Laboratories, and Lilly Laboratory for Clinical Research, Indianapolis, Indiana 46202, USA.
Study Objective: To test whether olanzapine, an atypical antipsychotic, is an inhibitor of cytochrome P450 (CYP) 1A2 activity, we conducted a drug interaction study with theophylline, a known CYP1A2 substrate.
Design: Two-way, randomized, crossover study.
Setting: Clinical research laboratory.